Table 1 Baseline demographics and disease characteristics
| Â | Placebo | Indigo naturalis | Total |
|---|---|---|---|
Patients randomized, n | 8 | 16 | 24 |
Men, n (%) | 7 (87.5) | 10 (62.5) | 17 (70.8) |
Race, n (%) | |||
 Asian | 8 (100) | 16 (100) | 24 (100) |
Age, years | 40.1 ± 10.9 | 39.3 ± 10.1 | 39.6 ± 10.1 |
Weight, kg | 74.1 ± 16.7 | 73.2 ± 16.0 | 73.5 ± 15.9 |
Body mass index (kg/m2) | 25.2 ± 4.6 | 25.9 ± 3.9 | 25.7 ± 4.0 |
Duration of psoriasis, years | 14.9 ± 12.1 | 13.1 ± 11.1 | 13.7 ± 11.2 |
Age at diagnosis, years | 25.3 ± 13.3 | 26.2 ± 12.0 | 25.7 ± 11.2 |
BSA involvement (%), | 9.6 ± 5.8 | 8.4 ± 5.8 | 8.8 ± 5.7 |
PASI score (0–72) | 11.1 ± 3.7 | 10.1 ± 4.3 | 10.4 ± 4.0 |
 ≥ 10, n (%) | 4 (50.0) | 8 (50.0) | 12 (50.0) |
 < 10, n (%) | 4 (50.0) | 8 (50.0) | 12 (50.0) |
PGA score | 3.3 ± 0.5 | 3.0 ± 0.5 | 3.1 ± 0.5 |
OTPSS | 3.8 ± 0.5 | 3.6 ± 0.5 | 3.6 ± 0.5 |